featured
Brigatinib for ROS1 Fusion–Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study
ESMO Open 2024 Jul 16;9(8)103642, S Niho, Y Goto, R Toyozawa, H Daga, K Ohashi, T Takahashi, H Tanaka, J Sakakibara-Konishi, Y Hattori, M Morise, M Kodani, T Ikeda, H Izumi, S Matsumoto, K Yoh, S Nomura, K GotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.